Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients.
Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer.
Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers.
Company Details
- Employees
- 43
- Founded
- -
- Address
- Gullhaugveien 7, Oslo,oslo 0484,norway
- Phone
- 4722183305
- kv****@****ent.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- oncoinvent.com
- HQ
- Oslo, Oslo
Oncoinvent Asa Questions
Oncoinvent Asa's helpline number is 4722183305
Oncoinvent Asa's website is oncoinvent.com
Oncoinvent Asa's LinkedIn profile is https://no.linkedin.com/company/oncoinvent-as
Oncoinvent Asa has
43 employees.
View email and phone details for 43
employees at Oncoinvent Asa.
Oncoinvent Asa's industry is
Biotechnology Research
Oncoinvent Asa's top competitors are
Ultimovacs Asa,
Thor Medical Asa,
Zenas Biopharma,
Lytix Biopharma,
Hadean Ventures,
Bergenbio Asa,
Artbio,
Nykode Therapeutics,
Zelluna,
Ge Healthcare.
Oncoinvent Asa's support email address is kvam@oncoinvent.com
Oncoinvent Asa's categories are Biotechnology Research
Oncoinvent Asa's founding year is 2010
